Freya Biosciences, a clinical-stage biotech company, has raised $38M Series A funding to advance the development of innovative women’s reproductive immunotherapies. The funding round was led by Sofinnova Partners and OMX Ventures with participation from The Export and Investment Fund of Denmark, Angelini Ventures, Mike Jafar Family Office, CE-Ventures, Corundum Systems Biology, and Indaco Venture Partners.
Freya Biosciences’ Series A comes on the heels of positive top-line clinical results, which have significantly fueled the advancement of their lead drug candidate. The company’s primary focus is on a novel vaginal microbial immunotherapeutic designed for women with dysbiotic vaginal microbiota undergoing assisted reproductive technology (ART). Additionally, the new funds will enhance Freya’s multiomics data science platform, encompassing deep microbiome sequencing and extensive immune biomarker profiling in human clinical samples.
“We are very excited to announce Freya’s Series A fundraise, with the support of this dedicated team of investors,” said Colleen Acosta, CEO of Freya Biosciences. “Conditions that disproportionately and differently affect women have traditionally been underfunded in proportion to its burden on human health. Freya’s initial focus is on the millions of couples around the world who are struggling with infertility. This funding enables us to advance our groundbreaking immunotherapy platform targeting the vaginal microbiota and unlock its therapeutic potential in this area and beyond.”
“Freya’s team of experts are uniquely positioned to shape a more comprehensive understanding of women’s health and disease to advance innovative solutions and novel treatment paradigms and we are confident in their success,” said Henrijette Richter, Managing Partner at Sofinnova Partners. “We look forward to supporting Freya as they continue to advance microbial immunotherapies to address reproductive health issues for which there are no treatments available.”
“OMX is proud to support Freya’s mission in women’s health and excited for Freya’s promising initial clinical results,” said Nick Haft, CEO of OMX Ventures. “We invest in trailblazing companies and Freya’s platform using microbial immunotherapies, supported by recent positive topline clinical results, has the potential to address a range of health conditions that uniquely affect women.”
